nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00749	0.0826	CbGeAlD
Escitalopram—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00633	0.00722	CcSEcCtD
Escitalopram—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00633	0.00722	CcSEcCtD
Escitalopram—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00712	CcSEcCtD
Escitalopram—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00608	0.00693	CcSEcCtD
Escitalopram—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00608	0.00693	CcSEcCtD
Escitalopram—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00605	0.0667	CbGeAlD
Escitalopram—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00666	CcSEcCtD
Escitalopram—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00585	0.00666	CcSEcCtD
Escitalopram—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00577	0.00658	CcSEcCtD
Escitalopram—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00577	0.00658	CcSEcCtD
Escitalopram—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.0057	0.0065	CcSEcCtD
Escitalopram—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00563	0.00642	CcSEcCtD
Escitalopram—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00563	0.00642	CcSEcCtD
Escitalopram—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00563	0.00642	CcSEcCtD
Escitalopram—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00561	0.0619	CbGeAlD
Escitalopram—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00557	0.00634	CcSEcCtD
Escitalopram—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.0055	0.00627	CcSEcCtD
Escitalopram—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00619	CcSEcCtD
Escitalopram—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00619	CcSEcCtD
Escitalopram—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00537	0.00612	CcSEcCtD
Escitalopram—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00531	0.00605	CcSEcCtD
Escitalopram—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00525	0.00599	CcSEcCtD
Escitalopram—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00525	0.00599	CcSEcCtD
Escitalopram—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00514	0.0567	CbGeAlD
Escitalopram—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00509	0.0058	CcSEcCtD
Escitalopram—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00498	0.00567	CcSEcCtD
Escitalopram—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00493	0.00562	CcSEcCtD
Escitalopram—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00488	0.00556	CcSEcCtD
Escitalopram—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00488	0.00556	CcSEcCtD
Escitalopram—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00478	0.00545	CcSEcCtD
Escitalopram—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00473	0.0054	CcSEcCtD
Escitalopram—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00469	0.00534	CcSEcCtD
Escitalopram—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00464	0.00529	CcSEcCtD
Escitalopram—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00464	0.00529	CcSEcCtD
Escitalopram—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.0046	0.00524	CcSEcCtD
Escitalopram—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00456	0.00519	CcSEcCtD
Escitalopram—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00452	0.00515	CcSEcCtD
Escitalopram—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00452	0.00515	CcSEcCtD
Escitalopram—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00452	0.00515	CcSEcCtD
Escitalopram—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0051	CcSEcCtD
Escitalopram—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0051	CcSEcCtD
Escitalopram—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00505	CcSEcCtD
Escitalopram—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00505	CcSEcCtD
Escitalopram—Mania—Riluzole—amyotrophic lateral sclerosis	0.0044	0.00501	CcSEcCtD
Escitalopram—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00428	0.00488	CcSEcCtD
Escitalopram—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00484	CcSEcCtD
Escitalopram—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00484	CcSEcCtD
Escitalopram—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.00421	0.0464	CbGeAlD
Escitalopram—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00414	0.00472	CcSEcCtD
Escitalopram—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00404	0.0046	CcSEcCtD
Escitalopram—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00453	CcSEcCtD
Escitalopram—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00453	CcSEcCtD
Escitalopram—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00395	0.0045	CcSEcCtD
Escitalopram—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00389	0.00443	CcSEcCtD
Escitalopram—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00439	CcSEcCtD
Escitalopram—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00423	CcSEcCtD
Escitalopram—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00417	CcSEcCtD
Escitalopram—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00364	0.00415	CcSEcCtD
Escitalopram—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00361	0.00412	CcSEcCtD
Escitalopram—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00406	CcSEcCtD
Escitalopram—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00403	CcSEcCtD
Escitalopram—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00401	CcSEcCtD
Escitalopram—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00401	CcSEcCtD
Escitalopram—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00398	CcSEcCtD
Escitalopram—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00395	CcSEcCtD
Escitalopram—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00345	0.00393	CcSEcCtD
Escitalopram—Gout—Riluzole—amyotrophic lateral sclerosis	0.00342	0.0039	CcSEcCtD
Escitalopram—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00388	CcSEcCtD
Escitalopram—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00385	CcSEcCtD
Escitalopram—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00385	CcSEcCtD
Escitalopram—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00385	CcSEcCtD
Escitalopram—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00383	CcSEcCtD
Escitalopram—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00327	0.00373	CcSEcCtD
Escitalopram—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00325	0.00371	CcSEcCtD
Escitalopram—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00369	CcSEcCtD
Escitalopram—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00322	0.0355	CbGeAlD
Escitalopram—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00364	CcSEcCtD
Escitalopram—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00364	CcSEcCtD
Escitalopram—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00364	CcSEcCtD
Escitalopram—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00364	CcSEcCtD
Escitalopram—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0036	CcSEcCtD
Escitalopram—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0036	CcSEcCtD
Escitalopram—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00312	0.00356	CcSEcCtD
Escitalopram—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00311	0.0343	CbGeAlD
Escitalopram—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00352	CcSEcCtD
Escitalopram—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00352	CcSEcCtD
Escitalopram—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.00308	0.0969	CbGpPWpGaD
Escitalopram—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00348	CcSEcCtD
Escitalopram—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00346	CcSEcCtD
Escitalopram—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.003	0.00342	CcSEcCtD
Escitalopram—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.003	0.00342	CcSEcCtD
Escitalopram—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00295	0.0325	CbGeAlD
Escitalopram—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00335	CcSEcCtD
Escitalopram—Coma—Riluzole—amyotrophic lateral sclerosis	0.00292	0.00333	CcSEcCtD
Escitalopram—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00329	CcSEcCtD
Escitalopram—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00329	CcSEcCtD
Escitalopram—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00319	CcSEcCtD
Escitalopram—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00316	CcSEcCtD
Escitalopram—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00316	CcSEcCtD
Escitalopram—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00313	CcSEcCtD
Escitalopram—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0031	CcSEcCtD
Escitalopram—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0031	CcSEcCtD
Escitalopram—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00307	CcSEcCtD
Escitalopram—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00304	CcSEcCtD
Escitalopram—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00304	CcSEcCtD
Escitalopram—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.0026	0.0286	CbGeAlD
Escitalopram—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00296	CcSEcCtD
Escitalopram—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00296	CcSEcCtD
Escitalopram—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00294	CcSEcCtD
Escitalopram—Injury—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00288	CcSEcCtD
Escitalopram—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00285	CcSEcCtD
Escitalopram—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00248	0.0273	CbGeAlD
Escitalopram—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00281	CcSEcCtD
Escitalopram—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00281	CcSEcCtD
Escitalopram—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00279	CcSEcCtD
Escitalopram—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00278	CcSEcCtD
Escitalopram—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00241	0.0266	CbGeAlD
Escitalopram—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00274	CcSEcCtD
Escitalopram—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00272	CcSEcCtD
Escitalopram—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00271	CcSEcCtD
Escitalopram—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00265	CcSEcCtD
Escitalopram—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00264	CcSEcCtD
Escitalopram—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00264	CcSEcCtD
Escitalopram—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00264	CcSEcCtD
Escitalopram—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00262	CcSEcCtD
Escitalopram—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0026	CcSEcCtD
Escitalopram—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0026	CcSEcCtD
Escitalopram—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00258	CcSEcCtD
Escitalopram—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00255	CcSEcCtD
Escitalopram—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00251	CcSEcCtD
Escitalopram—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00251	CcSEcCtD
Escitalopram—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.0022	0.0025	CcSEcCtD
Escitalopram—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00249	CcSEcCtD
Escitalopram—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.00217	0.0239	CbGeAlD
Escitalopram—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00246	CcSEcCtD
Escitalopram—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00244	CcSEcCtD
Escitalopram—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00241	CcSEcCtD
Escitalopram—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00241	CcSEcCtD
Escitalopram—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00239	CcSEcCtD
Escitalopram—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00238	CcSEcCtD
Escitalopram—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00234	CcSEcCtD
Escitalopram—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00233	CcSEcCtD
Escitalopram—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00233	CcSEcCtD
Escitalopram—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00202	0.0023	CcSEcCtD
Escitalopram—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00229	CcSEcCtD
Escitalopram—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00229	CcSEcCtD
Escitalopram—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00229	CcSEcCtD
Escitalopram—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.002	0.0221	CbGeAlD
Escitalopram—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00224	CcSEcCtD
Escitalopram—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00223	CcSEcCtD
Escitalopram—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00193	0.0213	CbGeAlD
Escitalopram—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0022	CcSEcCtD
Escitalopram—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00219	CcSEcCtD
Escitalopram—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00217	CcSEcCtD
Escitalopram—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00214	CcSEcCtD
Escitalopram—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00211	CcSEcCtD
Escitalopram—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0021	CcSEcCtD
Escitalopram—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00183	0.0202	CbGeAlD
Escitalopram—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00209	CcSEcCtD
Escitalopram—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00208	CcSEcCtD
Escitalopram—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00207	CcSEcCtD
Escitalopram—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00181	0.02	CbGeAlD
Escitalopram—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00205	CcSEcCtD
Escitalopram—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00204	CcSEcCtD
Escitalopram—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00204	CcSEcCtD
Escitalopram—Depression—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00203	CcSEcCtD
Escitalopram—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00201	CcSEcCtD
Escitalopram—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00175	0.002	CcSEcCtD
Escitalopram—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00175	0.002	CcSEcCtD
Escitalopram—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00199	CcSEcCtD
Escitalopram—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00199	CcSEcCtD
Escitalopram—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00198	CcSEcCtD
Escitalopram—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00195	CcSEcCtD
Escitalopram—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00194	CcSEcCtD
Escitalopram—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00193	CcSEcCtD
Escitalopram—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00192	CcSEcCtD
Escitalopram—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00169	0.0186	CbGeAlD
Escitalopram—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00191	CcSEcCtD
Escitalopram—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0019	CcSEcCtD
Escitalopram—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00186	CcSEcCtD
Escitalopram—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00163	0.018	CbGeAlD
Escitalopram—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00162	0.0179	CbGeAlD
Escitalopram—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00184	CcSEcCtD
Escitalopram—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00183	CcSEcCtD
Escitalopram—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00183	CcSEcCtD
Escitalopram—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00183	CcSEcCtD
Escitalopram—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00182	CcSEcCtD
Escitalopram—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00182	CcSEcCtD
Escitalopram—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00182	CcSEcCtD
Escitalopram—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00159	0.0175	CbGeAlD
Escitalopram—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00181	CcSEcCtD
Escitalopram—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0018	CcSEcCtD
Escitalopram—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0018	CcSEcCtD
Escitalopram—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00179	CcSEcCtD
Escitalopram—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.00157	0.0173	CbGeAlD
Escitalopram—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00154	0.017	CbGeAlD
Escitalopram—CHRM1—nervous system—amyotrophic lateral sclerosis	0.00154	0.017	CbGeAlD
Escitalopram—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00173	CcSEcCtD
Escitalopram—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00171	CcSEcCtD
Escitalopram—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0017	CcSEcCtD
Escitalopram—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00149	0.0164	CbGeAlD
Escitalopram—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.00148	0.0163	CbGeAlD
Escitalopram—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00166	CcSEcCtD
Escitalopram—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.00145	0.0456	CbGpPWpGaD
Escitalopram—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00165	CcSEcCtD
Escitalopram—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00165	CcSEcCtD
Escitalopram—Chills—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00164	CcSEcCtD
Escitalopram—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00163	CcSEcCtD
Escitalopram—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00142	0.0157	CbGeAlD
Escitalopram—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00162	CcSEcCtD
Escitalopram—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00141	0.0016	CcSEcCtD
Escitalopram—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00159	CcSEcCtD
Escitalopram—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00157	CcSEcCtD
Escitalopram—Tension—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00156	CcSEcCtD
Escitalopram—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00156	CcSEcCtD
Escitalopram—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00136	0.015	CbGeAlD
Escitalopram—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00155	CcSEcCtD
Escitalopram—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00154	CcSEcCtD
Escitalopram—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00153	CcSEcCtD
Escitalopram—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00131	0.0144	CbGeAlD
Escitalopram—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00149	CcSEcCtD
Escitalopram—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00148	CcSEcCtD
Escitalopram—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00147	CcSEcCtD
Escitalopram—SLC6A3—brain—amyotrophic lateral sclerosis	0.00129	0.0142	CbGeAlD
Escitalopram—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00146	CcSEcCtD
Escitalopram—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00145	CcSEcCtD
Escitalopram—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.00126	0.0139	CbGeAlD
Escitalopram—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00144	CcSEcCtD
Escitalopram—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00143	CcSEcCtD
Escitalopram—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00143	CcSEcCtD
Escitalopram—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00143	CcSEcCtD
Escitalopram—HTR2C—brain—amyotrophic lateral sclerosis	0.00125	0.0137	CbGeAlD
Escitalopram—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00124	0.039	CbGpPWpGaD
Escitalopram—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00141	CcSEcCtD
Escitalopram—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0014	CcSEcCtD
Escitalopram—Cough—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00139	CcSEcCtD
Escitalopram—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.00122	0.0134	CbGeAlD
Escitalopram—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00138	CcSEcCtD
Escitalopram—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00137	CcSEcCtD
Escitalopram—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.00119	0.0131	CbGeAlD
Escitalopram—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00136	CcSEcCtD
Escitalopram—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00136	CcSEcCtD
Escitalopram—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00136	CcSEcCtD
Escitalopram—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00135	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00135	CcSEcCtD
Escitalopram—SLC6A4—brain—amyotrophic lateral sclerosis	0.00118	0.013	CbGeAlD
Escitalopram—CHRM1—brain—amyotrophic lateral sclerosis	0.00118	0.013	CbGeAlD
Escitalopram—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00134	CcSEcCtD
Escitalopram—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00133	CcSEcCtD
Escitalopram—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00131	CcSEcCtD
Escitalopram—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0013	CcSEcCtD
Escitalopram—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0013	CcSEcCtD
Escitalopram—Infection—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00129	CcSEcCtD
Escitalopram—Shock—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00128	CcSEcCtD
Escitalopram—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00127	CcSEcCtD
Escitalopram—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00127	CcSEcCtD
Escitalopram—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00127	CcSEcCtD
Escitalopram—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00126	CcSEcCtD
Escitalopram—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00126	CcSEcCtD
Escitalopram—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.0011	0.0346	CbGpPWpGaD
Escitalopram—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00124	CcSEcCtD
Escitalopram—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00121	CcSEcCtD
Escitalopram—SLC6A2—brain—amyotrophic lateral sclerosis	0.00104	0.0115	CbGeAlD
Escitalopram—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00118	CcSEcCtD
Escitalopram—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00118	CcSEcCtD
Escitalopram—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00117	CcSEcCtD
Escitalopram—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00116	CcSEcCtD
Escitalopram—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00116	CcSEcCtD
Escitalopram—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.001	0.00114	CcSEcCtD
Escitalopram—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000991	0.00113	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000985	0.00112	CcSEcCtD
Escitalopram—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00112	CcSEcCtD
Escitalopram—HRH1—nervous system—amyotrophic lateral sclerosis	0.000979	0.0108	CbGeAlD
Escitalopram—Pain—Riluzole—amyotrophic lateral sclerosis	0.000975	0.00111	CcSEcCtD
Escitalopram—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000975	0.00111	CcSEcCtD
Escitalopram—ADRA1A—brain—amyotrophic lateral sclerosis	0.000966	0.0107	CbGeAlD
Escitalopram—ADRA1A—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.000952	0.03	CbGpPWpGaD
Escitalopram—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.000951	0.0299	CbGpPWpGaD
Escitalopram—HRH1—central nervous system—amyotrophic lateral sclerosis	0.000942	0.0104	CbGeAlD
Escitalopram—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00094	0.00107	CcSEcCtD
Escitalopram—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000933	0.00106	CcSEcCtD
Escitalopram—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00103	CcSEcCtD
Escitalopram—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00103	CcSEcCtD
Escitalopram—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00103	CcSEcCtD
Escitalopram—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.000861	0.0271	CbGpPWpGaD
Escitalopram—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00084	0.000957	CcSEcCtD
Escitalopram—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000818	0.000932	CcSEcCtD
Escitalopram—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.000817	0.0257	CbGpPWpGaD
Escitalopram—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000807	0.000919	CcSEcCtD
Escitalopram—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00078	0.000889	CcSEcCtD
Escitalopram—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.000779	0.0245	CbGpPWpGaD
Escitalopram—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.000762	0.024	CbGpPWpGaD
Escitalopram—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000757	0.00834	CbGeAlD
Escitalopram—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000754	0.000859	CcSEcCtD
Escitalopram—HRH1—brain—amyotrophic lateral sclerosis	0.000748	0.00825	CbGeAlD
Escitalopram—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000745	0.00821	CbGeAlD
Escitalopram—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.000735	0.0231	CbGpPWpGaD
Escitalopram—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000729	0.00803	CbGeAlD
Escitalopram—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000725	0.000826	CcSEcCtD
Escitalopram—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.000724	0.0228	CbGpPWpGaD
Escitalopram—Rash—Riluzole—amyotrophic lateral sclerosis	0.000719	0.000819	CcSEcCtD
Escitalopram—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000718	0.000819	CcSEcCtD
Escitalopram—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000717	0.0079	CbGeAlD
Escitalopram—Headache—Riluzole—amyotrophic lateral sclerosis	0.000714	0.000814	CcSEcCtD
Escitalopram—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000701	0.00772	CbGeAlD
Escitalopram—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000695	0.0219	CbGpPWpGaD
Escitalopram—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000677	0.000772	CcSEcCtD
Escitalopram—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000639	0.0201	CbGpPWpGaD
Escitalopram—CYP2D6—brain—amyotrophic lateral sclerosis	0.000569	0.00627	CbGeAlD
Escitalopram—CHRM1—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.000466	0.0147	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000466	0.0147	CbGpPWpGaD
Escitalopram—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.000435	0.0137	CbGpPWpGaD
Escitalopram—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000386	0.0121	CbGpPWpGaD
Escitalopram—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000337	0.0106	CbGpPWpGaD
Escitalopram—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000332	0.0104	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.0003	0.00945	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.0003	0.00945	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.0003	0.00945	CbGpPWpGaD
Escitalopram—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.0003	0.00944	CbGpPWpGaD
Escitalopram—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000298	0.00939	CbGpPWpGaD
Escitalopram—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000294	0.00925	CbGpPWpGaD
Escitalopram—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000282	0.00888	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000247	0.00779	CbGpPWpGaD
Escitalopram—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000243	0.00764	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000228	0.00719	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000221	0.00694	CbGpPWpGaD
Escitalopram—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000218	0.00685	CbGpPWpGaD
Escitalopram—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000215	0.00677	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—PFN1—amyotrophic lateral sclerosis	0.000212	0.00669	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000207	0.00651	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000202	0.00635	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000202	0.00635	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.00019	0.00597	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000188	0.0059	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000188	0.0059	CbGpPWpGaD
Escitalopram—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000187	0.00589	CbGpPWpGaD
Escitalopram—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000183	0.00576	CbGpPWpGaD
Escitalopram—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000182	0.00573	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000179	0.00563	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000175	0.00551	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000172	0.0054	CbGpPWpGaD
Escitalopram—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00017	0.00536	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000169	0.00532	CbGpPWpGaD
Escitalopram—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000167	0.00527	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000167	0.00526	CbGpPWpGaD
Escitalopram—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000166	0.00522	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000159	0.00501	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000155	0.00489	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000155	0.00486	CbGpPWpGaD
Escitalopram—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000153	0.00481	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000152	0.00479	CbGpPWpGaD
Escitalopram—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000146	0.00461	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000144	0.00452	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000144	0.00452	CbGpPWpGaD
Escitalopram—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000143	0.0045	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000141	0.00444	CbGpPWpGaD
Escitalopram—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000136	0.00427	CbGpPWpGaD
Escitalopram—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00013	0.00408	CbGpPWpGaD
Escitalopram—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000129	0.00407	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000128	0.00403	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000124	0.0039	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000119	0.00375	CbGpPWpGaD
Escitalopram—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000119	0.00375	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000103	0.00325	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000103	0.00324	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000103	0.00323	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000101	0.00319	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	9.96e-05	0.00314	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	9.11e-05	0.00287	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	9.09e-05	0.00286	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	9.08e-05	0.00286	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	8.72e-05	0.00274	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	8.72e-05	0.00274	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.47e-05	0.00267	CbGpPWpGaD
Escitalopram—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.06e-05	0.00254	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.97e-05	0.00251	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	7.87e-05	0.00248	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	7.84e-05	0.00247	CbGpPWpGaD
Escitalopram—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	7.78e-05	0.00245	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	7.77e-05	0.00245	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	7.76e-05	0.00244	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	7.73e-05	0.00243	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	7.73e-05	0.00243	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	7.72e-05	0.00243	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	6.89e-05	0.00217	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.59e-05	0.00207	CbGpPWpGaD
Escitalopram—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.79e-05	0.00182	CbGpPWpGaD
Escitalopram—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.71e-05	0.0018	CbGpPWpGaD
Escitalopram—ADRA1A—AMPK Signaling—TP53—amyotrophic lateral sclerosis	5.63e-05	0.00177	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.46e-05	0.00172	CbGpPWpGaD
Escitalopram—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.33e-05	0.00168	CbGpPWpGaD
Escitalopram—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.25e-05	0.00165	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.21e-05	0.00164	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.13e-05	0.00162	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.66e-05	0.00147	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.51e-05	0.00142	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.5e-05	0.00142	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.45e-05	0.0014	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	4.44e-05	0.0014	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	4.44e-05	0.0014	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.43e-05	0.0014	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.43e-05	0.00139	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.36e-05	0.00137	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.14e-05	0.0013	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.08e-05	0.00128	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.08e-05	0.00128	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	4.06e-05	0.00128	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	4.06e-05	0.00128	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.04e-05	0.00127	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.03e-05	0.00127	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.96e-05	0.00125	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.96e-05	0.00125	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.77e-05	0.00119	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.73e-05	0.00118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.63e-05	0.00114	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	3.55e-05	0.00112	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.48e-05	0.0011	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.47e-05	0.00109	CbGpPWpGaD
Escitalopram—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.43e-05	0.00108	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.43e-05	0.00108	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.42e-05	0.00108	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.42e-05	0.00108	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.37e-05	0.00106	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.26e-05	0.00103	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.24e-05	0.00102	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	3.21e-05	0.00101	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.15e-05	0.000991	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.14e-05	0.000988	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.14e-05	0.000987	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.09e-05	0.000972	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.96e-05	0.000932	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.95e-05	0.000929	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.95e-05	0.000929	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.9e-05	0.000914	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.81e-05	0.000883	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.8e-05	0.00088	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.78e-05	0.000876	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.75e-05	0.000867	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.75e-05	0.000867	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.72e-05	0.000855	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.71e-05	0.000852	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.67e-05	0.00084	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.67e-05	0.00084	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.67e-05	0.000839	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.44e-05	0.000768	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	2.43e-05	0.000766	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.43e-05	0.000765	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.41e-05	0.000759	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.4e-05	0.000757	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.39e-05	0.000751	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.38e-05	0.000748	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.37e-05	0.000745	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.34e-05	0.000737	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.3e-05	0.000724	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.27e-05	0.000714	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	2.24e-05	0.000706	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.24e-05	0.000705	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.24e-05	0.000704	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.13e-05	0.000672	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.06e-05	0.00065	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.04e-05	0.000643	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.03e-05	0.00064	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.99e-05	0.000628	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.99e-05	0.000626	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.96e-05	0.000616	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.94e-05	0.000611	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.93e-05	0.000609	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.93e-05	0.000607	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.9e-05	0.0006	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.89e-05	0.000595	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.84e-05	0.00058	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.77e-05	0.000558	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.76e-05	0.000555	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.76e-05	0.000553	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.73e-05	0.000544	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.69e-05	0.000533	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.69e-05	0.000532	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.68e-05	0.000529	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.64e-05	0.000516	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.63e-05	0.000514	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.61e-05	0.000506	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.54e-05	0.000484	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.53e-05	0.000482	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.51e-05	0.000475	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.46e-05	0.000461	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.46e-05	0.00046	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.46e-05	0.000459	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.45e-05	0.000455	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.44e-05	0.000452	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	0.000428	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.35e-05	0.000425	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.25e-05	0.000394	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.25e-05	0.000393	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.23e-05	0.000387	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.2e-05	0.000378	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.18e-05	0.000371	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.17e-05	0.00037	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.16e-05	0.000364	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.15e-05	0.000363	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.12e-05	0.000352	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.11e-05	0.000349	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.04e-05	0.000328	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.04e-05	0.000327	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.02e-05	0.000322	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.9e-06	0.000312	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.69e-06	0.000305	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.66e-06	0.000304	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.51e-06	0.000299	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.24e-06	0.000291	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.11e-06	0.000287	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.1e-06	0.000286	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.37e-06	0.000263	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.01e-06	0.000252	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.98e-06	0.000251	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.86e-06	0.000247	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	7.49e-06	0.000236	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.12e-06	0.000224	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	6.89e-06	0.000217	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.72e-06	0.000212	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.17e-06	0.000194	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.15e-06	0.000193	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.05e-06	0.00019	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.04e-06	0.00019	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.96e-06	0.000187	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.83e-06	0.000183	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.81e-06	0.000183	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.72e-06	0.00018	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.47e-06	0.000172	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.23e-06	0.000165	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.22e-06	0.000164	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.13e-06	0.000162	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.13e-06	0.000162	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.72e-06	0.000149	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.56e-06	0.000144	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.5e-06	0.000142	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.95e-06	0.000124	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.94e-06	0.000124	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.88e-06	0.000122	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.09e-06	9.71e-05	CbGpPWpGaD
